The ABCC3 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population with targeted disruption of the ABCC3 gene in human SK-HEP-1 liver adenocarcinoma cells. This loss-of-function model for the multidrug resistance-associated protein 3 (MRP3) is generated via CRISPR/Cas9-mediated gene disruption. The polyclonal format provides a heterogeneous knockout mixture that better reflects tumor cell genetic diversity, making it suitable for pharmacological and functional investigations.
SK-HEP-1 is a human liver adenocarcinoma cell line derived from ascites, frequently used for hepatocarcinogenesis and drug metabolism research. Despite exhibiting some endothelial traits, it remains a standard model for studying hepatic transport, uptake, and metabolic pathways. Its well-characterized baseline transporter expression and ease of culture make it an ideal host for generating transporter knockout models.
ABCC3 encodes MRP3, an ATP-dependent transporter that effluxes organic anions, including glucuronide and glutathione conjugates, bile acids, and chemotherapeutic agents such as methotrexate and etoposide. The gene is transcriptionally regulated by NRF2 under oxidative stress, by bile acid sensor FXR, and by xenobiotic receptors PXR and CAR, with additional modulation by cytokines TNF-?? and IL-1??. MRP3 interacts with scaffold proteins PDZK1 and NHERF1 and functionally cooperates with glutathione S-transferases (GSTs) and UDP-glucuronosyltransferases (UGTs). Its activity reduces intracellular drug levels and contributes to cellular detoxification and bile acid secretion, positioning it at the nexus of drug resistance and hepatic transport pathways.
ABCC3 knockout in SK-HEP-1 cells impairs organic anion efflux, leading to increased intracellular accumulation of chemotherapeutic agents and potential sensitization to drug-induced cytotoxicity. This model enables dissection of MRP3’s role in multidrug resistance in hepatocellular carcinoma and its interplay with other ABC transporters like ABCB1, ABCC1, and ABCC2. It is also valuable for studying bile acid homeostasis, cholestasis, and drug-induced liver injury, where MRP3-mediated transport is critical. The system allows examination of NRF2-mediated antioxidant responses and FXR-regulated bile acid signaling in an isogenic background.
Applications include multidrug resistance studies, chemosensitivity screening, hepatobiliary transport assays, and drug metabolism profiling. Assays such as flow cytometry with calcein-AM or mitoxantrone measure transporter activity; western blotting and RT-qPCR confirm knockout efficiency and compensatory changes; MTT cytotoxicity assays evaluate drug sensitivity; and intracellular accumulation or bile acid transport assays assess substrate handling. These approaches support ABC transporter inhibitor development and hepatic transporter research. For technical inquiries or product orders, please contact Ascent Research.
